FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced new measures to make the development of biosimilar treatments faster, more efficient, and less costly. These updates simplify biosimilarity studies, reduce unnecessary clinical testing, and create clearer pathways for biosimilars to be developed as interchangeable with brand-name biologics. According to the Biosimilars Forum, these policy changes […]